[Agranulocytosis and transitory immune deficiency after fetal exposure to azathioprine and mesalazine].
Cissoko
H
H
Jonville-Béra
A P
AP
Lenain
H
H
Rivière
M F
MF
Saugier
J
J
Casanova
J L
JL
Autret-Leca
E
E
D000328:Adult; D000361:Agammaglobulinemia / Q000139:chemically induced*; D000380:Agranulocytosis / Q000139:chemically induced*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001379:Azathioprine / Q000009:adverse effects*; D016516:CD4-CD8 Ratio; D003424:Crohn Disease / Q000188:drug therapy; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008431:Maternal-Fetal Exchange; D019804:Mesalamine / Q000009:adverse effects*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D019804:Mesalamine; D001379:Azathioprine